| First Author | Brothers BA | Year | 2025 |
| Journal | Commun Biol | Volume | 8 |
| Issue | 1 | Pages | 1654 |
| PubMed ID | 41286353 | Mgi Jnum | J:375440 |
| Mgi Id | MGI:8265840 | Doi | 10.1038/s42003-025-09045-0 |
| Citation | Brothers BA, et al. (2025) Molecular mechanisms limiting the AAV gene therapy treatment window in mouse models of blue cone monochromacy. Commun Biol 8(1):1654 |
| abstractText | Blue cone monochromacy (BCM) is a severe X-linked blinding disorder caused by mutations in the OPN1LW/OPN1MW locus, resulting in impaired cone function and structural degeneration. We conduct a comparative analysis of AAV gene therapy in Opn1mw(-/-)/Opn1sw(-/-) (double knockout, DKO) and Opn1mw(C198R)/Opn1sw(-/-) (C198R) BCM mouse models to contrast therapeutic outcomes at different stages. We demonstrate the AAV8(Y733F) capsid achieves superior rescue compared to AAV5. Both DKO and C198R models show comparable therapeutic outcomes, with efficacy consistently decreasing in older mice. Structural analysis reveals both models display rapid degenerative changes in cone outer and inner segments. We observe age-related reductions in transgene expression for both models, potentially resulting from decreased cone transducibility, transgene silencing/downregulation, or disease-related genome expression alterations. Notably, the Pde6c and Cngb3 promoters maintain robust activity in degenerating cones. These findings suggest use of an optimized cone promoter can ultimately extend the therapeutic window and treatment longevity in BCM cones. |
